Press Release

AB-Therapeutics Announces Participation In Bio 2011 Annual International Convention in Washington, DC

June 14, 2011

AB-Therapeutics SL, a clinical-stage pharmaceutical biotech company in early 2012, today announced that Carles Domènech, PhD, chief executive officer and executive vice president of business development, will participate at the BIO 2011 Annual International Convention in Washington , DC from June 27 to June 30. During the convention he will meet with investors for its € 3 Milion series A financing round and will explore R&D collaborations with pharmaceutical companies.

AB-Therapeutics is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a product ABT0812 in regulatory preclinical development, with Phase I clinical trials (first in man) starting early 2012. A second drug candidate ABT1014 will start preclinical development in 4Q2011.

Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
 
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG